Somewhat Positive Media Coverage Somewhat Unlikely to Impact Dicerna Pharmaceuticals (NASDAQ:DRNA) Share Price

Press coverage about Dicerna Pharmaceuticals (NASDAQ:DRNA) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.3738462507211 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Dicerna Pharmaceuticals (DRNA) opened at 3.00 on Friday. The stock has a 50 day moving average price of $3.46 and a 200 day moving average price of $3.12. The company’s market cap is $62.53 million. Dicerna Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $6.10.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.54. The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.08 million. Dicerna Pharmaceuticals had a negative return on equity of 168.65% and a negative net margin of 8,474.12%. The company’s revenue for the quarter was up 2400.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.75) EPS. On average, equities analysts forecast that Dicerna Pharmaceuticals will post ($2.73) earnings per share for the current year.

A number of research firms have commented on DRNA. Chardan Capital restated a “hold” rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th. ValuEngine lowered Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 23rd. Finally, Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has an average rating of “Hold” and an average target price of $6.35.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

What are top analysts saying about Dicerna Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dicerna Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit